{"id":791265,"date":"2024-11-29T08:03:27","date_gmt":"2024-11-29T13:03:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/"},"modified":"2024-11-29T08:03:27","modified_gmt":"2024-11-29T13:03:27","slug":"tg-therapeutics-to-participate-in-the-evercore-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/","title":{"rendered":"TG Therapeutics to Participate in the Evercore HealthCONx Conference"},"content":{"rendered":"<h2>\nFireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>NEW YORK, Nov.  29, 2024  (GLOBE NEWSWIRE) &#8212; TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company\u2019s Chairman and Chief Executive Officer, will participate in the 7<sup>th<\/sup> Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET.<\/p>\n<p>A live webcast of the fireside chat will be available on the Events page, located within the Investors &amp; Media section, of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dL832ZOnrlYV3Zk6Qgar_x27jBS9DqMyrCnPuoIjy82WaIm0TuAj_EtxpUFPokmg6VAwVDAdJwLN-IC88aYUPLYpSvlZCN7M47EgQWigNVifaUeBumdE4ri_-NnLQ8kH\" rel=\"nofollow\" target=\"_blank\">http:\/\/ir.tgtherapeutics.com\/events<\/a>.<\/p>\n<p>\n        <strong>ABOUT TG THERAPEUTICS<\/strong><br \/>\n        <br \/>TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI<sup>\u00ae<\/sup> (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bTovtGMuh_yg6b1nsCNnFd9a07BVcNZTkVpK9O9MGpSyl5IWOqFbGU9GT_BEjuWqZHolu5J6IFfaUashrn3i26rJmEkD8R5CbKP_EkI1XZM=\" rel=\"nofollow\" target=\"_blank\">www.tgtherapeutics.com<\/a>, and follow us on X (formerly Twitter)\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VYXdWDneLgP61L_8GcX6VXU9A7AkYJnlKI0v0DF3qsqwc49ByqSEU96pvEfG31xWkunGwOLodsakxWMhbpv7Pk4aONfy28-WzorJ1M9Pm3g=\" rel=\"nofollow\" target=\"_blank\">@TGTherapeutics<\/a> and on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IO3PJUzAJ8Z3zbd81qrNaFajti_vWD0UtIwdhA2sKW5XCkmFkO99kmKxT1C850g0plEqoepm9P4RM8tvJJ0qF0w6LGFiOMe9MfY4CnCxYTD_sz7VrflzUccL5uuuor85\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>BRIUMVI<sup>\u00ae<\/sup> is a registered trademark of TG Therapeutics, Inc.<\/p>\n<p>CONTACT:<\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Email: ir@tgtxinc.com<br \/>Telephone: 1.877.575.TGTX (8489), Option 4<\/p>\n<p>\n        <strong>Media Relations:<\/strong><br \/>\n        <br \/>Email: media@tgtxinc.com<br \/>Telephone: 1.877.575.TGTX (8489), Option 6<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjEyN2U5YjYtNDNjYy00NDcwLWE2MDMtMTliMzZkMGM5MTIwLTEwMzIxMzA=\/tiny\/TG-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) &#8212; TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company\u2019s Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors &amp; Media section, of the Company\u2019s website at http:\/\/ir.tgtherapeutics.com\/events. ABOUT TG THERAPEUTICS TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TG Therapeutics to Participate in the Evercore HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791265","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TG Therapeutics to Participate in the Evercore HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TG Therapeutics to Participate in the Evercore HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) &#8212; TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company\u2019s Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors &amp; Media section, of the Company\u2019s website at http:\/\/ir.tgtherapeutics.com\/events. ABOUT TG THERAPEUTICS TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the &hellip; Continue reading &quot;TG Therapeutics to Participate in the Evercore HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-29T13:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TG Therapeutics to Participate in the Evercore HealthCONx Conference\",\"datePublished\":\"2024-11-29T13:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/\"},\"wordCount\":273,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/\",\"name\":\"TG Therapeutics to Participate in the Evercore HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=\",\"datePublished\":\"2024-11-29T13:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TG Therapeutics to Participate in the Evercore HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TG Therapeutics to Participate in the Evercore HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"TG Therapeutics to Participate in the Evercore HealthCONx Conference - Market Newsdesk","og_description":"Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) &#8212; TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company\u2019s Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors &amp; Media section, of the Company\u2019s website at http:\/\/ir.tgtherapeutics.com\/events. ABOUT TG THERAPEUTICS TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the &hellip; Continue reading \"TG Therapeutics to Participate in the Evercore HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2024-11-29T13:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TG Therapeutics to Participate in the Evercore HealthCONx Conference","datePublished":"2024-11-29T13:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/"},"wordCount":273,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/","name":"TG Therapeutics to Participate in the Evercore HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=","datePublished":"2024-11-29T13:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTcwMSM2NjE1ODI3IzIwMjA3OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tg-therapeutics-to-participate-in-the-evercore-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TG Therapeutics to Participate in the Evercore HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791265"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791265\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}